Aktienanalyse zu Tiziana Life Sciences Ltd (TLSA)TLSATiziana Life Sciences Ltd

Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer. It operates in the Healthcare sector.

Tiziana Life Sciences Ltd is currently not a good buy due to its very low RSI of 14.744, indicating extreme oversold conditions, and a significant 5-day price drop of 24.06%. While the analyst has a bullish target of $7, the stock is trading at only $0.67, which suggests a potential upside but also carries substantial risk given its recent performance and negative sentiment.